Matinas BioPharma Holdings, Inc. (MTNB)

MTNB Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-22.94	-21	-23.68	-23.24	-18.3
Depreciation & Amortization	0.94	0.9	0.78	0.77	0.78
Share-Based Compensation	4.95	5.23	4.29	4.56	2.99
Other Operating Activities	1.78	-4.29	2.99	-0.26	-0.49
Operating Cash Flow	-15.28	-19.16	-15.22	-17.37	-14.09
Capital Expenditures	-0.22	-0.89	-0.26	-0.01	-0.41
Change in Investments	13.46	5.77	17.03	-40.66	-5.61
Investing Cash Flow	13.24	4.88	16.77	-40.67	-6.01
Share Issuance / Repurchase	0	0.1	7	48.1	30.13
Debt Issued / Paid	-0.01	-0.02	-0.03	-0.05	-0.28
Financing Cash Flow	-0.01	0.08	6.97	48.05	29.85
Net Cash Flow	-2.04	-14.2	8.51	-9.99	9.75
Free Cash Flow	-15.5	-20.05	-15.48	-17.37	-14.5
Free Cash Flow Margin	-1413.87%	-628.86%	-46918.18%	-	-
Free Cash Flow Per Share	-0.07	-0.09	-0.07	-0.09	-0.10

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).